Compare FedEx Corporation (FDX) vs Repligen Corporation Common Stock (RGEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
FedEx Corporation vs Repligen Corporation Common Stock — how do they compare? FedEx Corporation trades at $291.96 (market cap $68.77B), while Repligen Corporation Common Stock trades at $178.15 (market cap $11.14B). The key difference: FedEx Corporation is far larger — about 6.2× Repligen Corporation Common Stock's market cap, and FedEx Corporation pays a 1.68% dividend while Repligen Corporation Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold FedEx Corporation for 87 Days and Repligen Corporation Common Stock for 0 Days on average.
| FDX | RGEN | |
|---|---|---|
Market Cap | $68.77B | $11.14B |
Volume | 914,308 | 1,259,263 |
Sector | Industrials | Health |
52-Week High | $339.35 | $194.57 |
52-Week Low | $189.87 | $102.87 |
Typical Hold Time | 87 Days | 0 Days |
Enterprise Value | $98.41B | $11.02B |
Dividend Yield | 1.68% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FedEx (FDX) trades at $291.28, down 0.33% on the day, with a bearish technical signal. The stock shows solid fundamentals with a P/E of 15.67 and net income margin of 4.68%, though revenue has been flat recently. Recent news includes a $300 million electric truck order and shareholder approval of executive pay. Cash flow is projected to improve significantly in 2026.
The outlook is mixed: strong analyst buy consensus (57%) and a $307.55 price target suggest upside, but technical indicators and rising fuel costs pose near-term risks. Long-term growth depends on execution of cost cuts and capitalizing on industry tailwinds.
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About FedEx Corporation
FedEx pioneered overnight delivery in 1973 and remains the world's largest express package provider. In its fiscal 2020 (ended May 2020), FedEx derived 51% of revenue from its express division, 33% from ground, and 10% from freight, its asset-based less-than-truckload shipping segment. The remainder comes from other services, including FedEx Office, which provides document production/shipping, and FedEx Logistics, which provides global forwarding. FedEx acquired Dutch parcel delivery firm TNT Express in 2016. TNT was previously the fourth-largest global parcel delivery provider.
Read more on FDX →About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →
